Skip to content
  1. Home
  2. Fitness & muscle
  3. CJC-1295 with DAC

Fitness & muscle

CJC-1295 with DAC

Long-acting GHRH analog with week-long half-life via albumin binding; distinct from daily-dosing CJC-1295.

Research compound Fitness & muscle Anti-aging Recovery & healing

Reviewed 2026-09-12
Full name
CJC-1295 drug affinity complex (GHRH analog with albumin-binding modification)
Also known as
CJC-1295 DAC, CJC-1295/DAC
Regulatory status
Research compound | Used in compounding pharmacies

Origin

A synthetic 30-amino-acid GHRH analog. The DAC (drug affinity complex) variant adds four lysine residues that bind serum albumin, stretching half-life from about 10 minutes to 7-10 days, unlike plain CJC-1295 (Mod GRF 1-29), which needs multiple daily doses.

Mechanism

A selective GHRH receptor agonist on somatotrophs, stimulating pulsatile GH release via Gs/cAMP signaling. Albumin binding blocks rapid renal clearance, which is what makes it long-acting.

Research summary

Evidence

GHRH analogs are potent GH stimulators used diagnostically and preclinically. CJC-1295 with DAC hasn't been extensively studied in published human trials; most evidence comes from compounding-pharmacy literature and community protocols. Its advantage over plain CJC-1295 is fewer injections, at the cost of less precise titration.

Evidence tier: Research compound — see the methodology note for how this is assessed.

Citations

No specific peer-reviewed citations indexed for this entry — see the research summary above for what evidence does exist.

Reported benefits

  • growth hormone stimulation
  • reduced injection frequency (weekly vs daily)
  • improved muscle mass
  • enhanced recovery

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
RouteReported protocol
Subcutaneous injection100-200 mcg to 2mg SC weekly; often stacked with GHRP-2 or GHRP-6.

Side effects

  • mild water retention
  • joint aches (rare)
  • carpal tunnel-like symptoms (rare)
  • cortisol elevation at high doses

Safety notes

Safety: Not FDA-approved. The key distinction from plain CJC-1295: DAC produces steady-state albumin-bound hormone instead of pulsatile dosing. Long-term human safety data is limited.
Community & reddit notes (anecdotal — not clinical evidence)

Widely used for convenient weekly dosing, frequently stacked with GHRP-2/6. It differs fundamentally from CJC-1295 without DAC (short half-life, about 30 minutes, requiring 2-3x daily dosing); the two get confused constantly despite being pharmacokinetically distinct compounds.

Used in stacks

Community combinations that include CJC-1295 with DAC — see each stack page for the combination-specific rationale and evidence.

Mixing compatibility

Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.

Used together in wellness-clinic protocols

Anecdotally combined (outside clinic protocols)

Reported as a combination to avoid